{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055838","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.590997+00:00","generated_at":"2026-06-03T02:41:29.838034+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO","bullets":["Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.","CEO Maria Maccecchini appointed as interim principal financial officer effective May 1, 2024.","Severance includes 2 months base salary ($62,500) plus $3,000 medical/dental reimbursement, paid as lump sum.","Company accelerates vesting of 10,000 stock options and extends exercise period for certain options through Dec 31, 2024.","Hagopian signed a separation agreement with a general release of claims and non-disparagement obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055838","json":"https://secwatch.observer/filing/0001104659-24-055838.json","markdown":"https://secwatch.observer/filing/0001104659-24-055838.md","text":"https://secwatch.observer/filing/0001104659-24-055838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/tm2413238d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:41:29.838034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33be74216a","claim":"Maria Maccecchini was appointed as interim principal financial officer at Annovis Bio, Inc..","evidence_excerpt":"On May 1, 2024, the Board appointed Maria Maccecchini, the Company’s President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian’s departure.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"bef80af3db","claim":"Henry Hagopian departed as Chief Financial Officer at Annovis Bio, Inc..","evidence_excerpt":"Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the “Company”). Mr. Hagopian is stepping down from these positions to pursue other opportunities.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924055838/0001104659-24-055838-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}